Petros Pharmaceuticals Featured in “New Era of Healthcare, AI, Data and Consumer Empowerment”

December 19, 2024 9:15 AM

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announced that in a recent podcast, The Intelligent Leadership Podcast, titled, "The New Era of Healthcare, AI, Data and Consumer Empowerment," Petros President Fady Boctor discussed the Company's concerted efforts to develop its proprietary platform...

Read more

Gene Guard Detox, Inc. Seeks Strategic Investors to Transform Newly Patented Toxin-Removal Science for Glyphosate & BPA Into Commercialization

December 19, 2024 9:00 AM

Gene Guard Detox, Inc., an innovative health and wellness company, is seeking strategic investment partners to commercialize its patented probiotics and postbiotics. Since its founding in 2019, the company has developed transformative solutions to address toxins such as glyphosate and BPA in humans and pets. Through proprietary research, Gene Guard Detox has demonstrated remarkable toxin-binding capabilities of its probiotic strains,...

Read more

Michael L. Baum, Esq. Renowned Advocate Added to Board of Gene Guard Detox, Inc.

December 18, 2024 9:00 AM

Gene Guard Detox, Inc. proudly welcomes Michael L. Baum, Esq. to its Board of Directors. An award-winning litigator and champion for victims of Drugs as well as glyphosate exposure, Baum has set new standards in environmental and health-related justice.Baum's exceptional legal career includes:Wisner Baum HPV vaccine attorneys are bringing the first Gardasil lawsuit to trial on January 21, 2025, in California State Court.Trial Team for the Lee...

Read more

Osceola County Commission Approves Negotiations With Medical Device Company to Establish Presence at NeoCity

December 17, 2024 4:30 PM

The Osceola County Board of County Commissioners has approved a Memorandum of Understanding (MOU) with Concept Companies and Empyrean Medical Systems, Inc., a global medical device technology company, marking another significant step in developing NeoCity as a premier technological innovation district.Under Monday's MOU, Empyrean would consider leasing space at NeoCity in 2025, focusing on advanced engineering and precision parts fabrication for...

Read more

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

December 17, 2024 9:15 AM

FRAMINGHAM, MA / ACCESSWIRE / December 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that announced that Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic participated in a Virtual Investor "What This Means" segment As part of...

Read more

Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually

December 17, 2024 9:00 AM

Working to identify quantum computing partnerships to strengthen our AI technology to include critical health records to better enable Rx to OTC switch candidates across multiple indicationsNEW YORK, NY / ACCESSWIRE / December 17, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces a...

Read more

Adnexus Biotechnologies Unveils Neural Temporal Fingerprinting for Personalized Health Monitoring Using Artificial Intelligence

December 17, 2024 7:00 AM

Adnexus Biotechnologies Inc. is proud to announce the launch of AI-Driven Neural Temporal Fingerprinting, a groundbreaking technology designed to predict and monitor neurological and cardiovascular conditions with unparalleled accuracy. This innovation is developed under the umbrella of the company's advanced AI platform, Sutra. The brain and heart of each person send signals with patterns of long and short signals, and EEG and ECG read these...

Read more

Kairos Pharma to Participate in The Microcap Conference in January 2025

December 16, 2024 12:15 PM

Kairos Pharma, (NYSE American:KAPA) a clinical stage biotechnology company is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.Kairos Pharma's management team will deliver a corporate presentation and engage in one-on-one meetings with institutional and...

Read more

“Greenwashing is Slowing Down the Energy Transition”: ThinkEnergy Urges a Shift Toward Genuine Solutions Driving Energy Transition

December 16, 2024 10:00 AM

As sustainability becomes a strategic priority for companies, it is alarming that 85% of global investors consider greenwashing a growing problem, according to EY's 2024 Institutional Investor Survey. This phenomenon not only undermines the credibility of environmental initiatives but also diverts critical resources away from projects that can make a real difference in combating climate change.Check out the EY's 2024 Institutional Investor...

Read more

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

December 16, 2024 9:30 AM

BASEL, SWITZERLAND and WALTHAM, MA / ACCESSWIRE / December 16, 2024 / Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharmaceutical company, today announced a research collaboration with the goal to accelerate the development of innovative treatments for autoimmune diseases.The collaboration will leverage Scailyte's proprietary AI platform, ScaiVision®, and Visterra's expertise in biologics...

Read more

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

December 16, 2024 9:00 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat cancers, today announced it has extended its previously announced Research Funding Agreement (the "Agreement") with the University of Virginia ("UVA") to advance the development of its systemic DNase program through 2025. Xenetic's DNase-based oncology platform...

Read more

Nabu Joins The Microcap Conference 2025 to Showcase AI Innovations in SEC Reporting

December 16, 2024 9:00 AM

Nabu, an AI tool that streamlines SEC reporting for public companies, is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.Nabu's management team will deliver a corporate presentation and engage in one-on-one meetings with institutional investors and public...

Read more

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

December 16, 2024 8:50 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the successful completion of the final wave of implants for shorter-term subjects in its six-month pre-clinical GLP study for enVVe, its transcatheter-delivered replacement venous valve. The successful completion of all planned implants in the GLP study, including both long-term and...

Read more

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

December 16, 2024 8:00 AM

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced plans for initiating a Phase 2 study evaluating TH104 in patients suffering from moderate-to-severe pruritus (severe itching) associated with primary biliary cholangitis (PBC), a rare and chronic liver disease, and also provided a corporate update. The launch of...

Read more

Elizabeth Fraley, CEO of Kinder Ready Introduces Executive Functioning (EF) Course, Boost Academic and Life Skills in Young Learners

December 13, 2024 4:30 AM

SANTA MONICA, CA / ACCESSWIRE / December 13, 2024 / Moving towards innovation, Elizabeth Fraley, CEO of Kinder Ready unveils an executive functioning (EF) course for early learners in a variety of areas, including planning, organization, self-control, task initiation, time management, metacognition, working memory, attention, flexibility, and perseverance. This holistic approach helps students learn the basic study and organizational skills they...

Read more

Last Day of Trading in Warrants Series TO 9 in Alligator Bioscience AB is 13 December 2024

December 13, 2024 2:20 AM

LUND, SE / ACCESSWIRE / December 13, 2024 / Alligator Bioscience (STO:ATORX) 13 December 2024 is the last day of trading in warrants series TO 9 in Alligator Bioscience AB ("Alligator Bioscience" or the "Company"). Subscription of ordinary shares by exercise of warrants series TO 9 is ongoing until 18 December 2024. One (1) warrant series TO 9 entitles the holder to subscribe for one (1) new ordinary share in the Company at a subscription price...

Read more

Introducing the HyperCAM Delta: The Revolutionary High Throughput HD-MEA, for Faster, More Accurate Data Collection

December 12, 2024 10:00 AM

The HyperCAM Delta is setting a new standard in High-Density Multi-Electrode Arrays (HD-MEAs), being the world's first to offer simultaneous recording from all wells and all electrodes in a 24-well format. Unlike currently available platforms that record from wells sequentially, the HyperCAM Delta empowers researchers to collect data from all 24 wells simultaneously, drastically reducing experimental times and simplifying workflows.Why Choose...

Read more

CIL Announces Breakthrough in Benzene Recovery, Addressing Cost, Environmental, and Supply Challenges for OLED Display Manufacturers

December 12, 2024 9:00 AM

TEWKSBURY, MA / ACCESSWIRE / December 12, 2024 / Cambridge Isotope Laboratories, Inc. (CIL) has successfully developed and implemented a game-changing benzene-d6 recovery program, addressing major pain points for manufacturers of organic light-emitting diode (OLED) displays. This innovative service reduces costs, minimizes environmental impact, and conserves scarce deuterium supplies.OLED display producers rely heavily on deuterated benzene...

Read more

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

December 12, 2024 8:45 AM

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kineta, Inc. (OTC PINK:KANT) ("Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, today announced that they have entered into a definitive merger agreement in...

Read more

Bionoid Pharma, Inc. Moves to Expand E-Commerce Presence With Binding Agreement to Acquire Platform From Vitawin Supplements Ltd.

December 12, 2024 7:30 AM

Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the signing of a Binding Letter of Intent (LOI) with Vitawin Supplements Ltd. to acquire its premier e-commerce platform, PrimeEnduro.com. This acquisition represents a significant milestone in Bionoid's strategic plan to expand its presence in the health and wellness sector through a scalable and AI-enhanced e-commerce ecosystem.The LOI outlines that Bionoid will retain all...

Read more